Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization
Background The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID-19 may derive from neutralizing antibodies (nAbs) to SARS-CoV-2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS-CoV-2, including Delta and Omicron, in CP donors previously infected with SARS-CoV-2 before and after immunization.
Methods and Materials Samples... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Harvala et al
- Copyright date:
- Rights statement:
- © 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record